Clearpoint Neuro (CLPT) Stock
MRI guided brain surgery platform for targeted drug delivery. Here's the price, business snapshot, and what's worth knowing about Clearpoint Neuro in October 2026.
ClearPoint Neuro (CLPT) develops MRI-guided platforms and instruments used in precision neurosurgery and targeted brain drug delivery. Its ClearPoint System enables real-time MRI visualisation during stereotactic procedures, helping clinicians place devices or deliver therapies such as intraparenchymal convection-enhanced delivery (CED). Revenue comes from system sales, single-use disposables and service contracts, plus partnerships with biopharma for therapy delivery. Investors often watch ClearPoint for clinical adoption trends, trial readouts and commercial partnerships that could broaden use cases. The company operates in a specialised, capital-intensive segment of medical devices where regulatory approvals, hospital purchasing cycles and reimbursement policies influence uptake. As a small-cap medical technology firm, ClearPoint can offer upside if its technology becomes standard in certain neurosurgical workflows, but faces execution and funding risks. This summary is educational only and not personal financial advice; values can rise or fall and past performance does not predict future returns.
Clearpoint Neuro (CLPT) Stock Forecast
Analyst price target, next 12 months
$21.67
+98.9% vs today's $10.90
Price range over the last 12 months
Close to its 12-month low
Analysts covering Clearpoint Neuro have a consensus 12-month target of $21.67, above the current price of $10.90.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 30 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Clearpoint Neuro's stock with a target price of $21.67, indicating good growth potential.
Financial Health
Clearpoint Neuro is generating moderate revenue and cash flow, with a solid gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Adoption Trend
Growing use of MRI-guided procedures could expand the addressable market, though adoption depends on hospital budgets, training and reimbursement.
Partnered Therapies
Collaborations for targeted drug delivery (CED) may create new revenue streams; clinical and regulatory hurdles can affect timing and outcomes.
Market Positioning
A specialised small-cap player with unique technology—offers potential upside if uptake increases, but expect volatility and funding risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
